30
Participants
Start Date
June 6, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2028
MAQ-001
MAQ-001 is an anti-PD-1 monoclonal antibody that inhibits T cell exhaustion through an alternative mechanism, independent of PD-1/PDL-1 blockade
Ipilimumab
Ipilimumab is a monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system
NOT_YET_RECRUITING
Centre Léon Bérard, Lyon
NOT_YET_RECRUITING
Institut Gustave Roussy, Paris
NOT_YET_RECRUITING
Centre Eugene Marquis, Rennes
RECRUITING
Oncopole Claudius Regaud Toulouse, Toulouse
Lead Sponsor
MabQuest SA
INDUSTRY